Whole mushrooms contain more than psilocybin — baeocystin, norbaeocystin, aeruginascin, and beta-carbolines like harmane and harmol. A 2024 Molecular Psychiatry study found mushroom extract moved more neuroplasticity markers in mice than chemically synthesized psilocybin at a matched dose, and a 2026 Scientific Reports simulation predicted an aeruginascin breakdown product may bind serotonin receptors more strongly than psilocin. Both are preclinical. Zero human trials have compared extract to synthetic head-to-head. Meanwhile every FDA-track program — COMP360, Usona — uses synthetic, because a trial needs a known number of milligrams. “Natural is stronger” is a live hypothesis, not a finding, and it is not a reason to skip screening or a container.
Watch the clip
DoubleBlind’s editor-in-chief on why the natural-versus-synthetic question matters for the future of psychedelic therapy. Watch on YouTube.
The short answer
Maybe, in mice. Whole-mushroom extract has outperformed matched-dose synthetic psilocybin on neuroplasticity markers in animals, and computational work suggests other mushroom alkaloids are pharmacologically busy. No human study has compared the two. Treat it as an open question, not a verdict.
DoubleBlind’s editor-in-chief framed it as a question about the future of psychedelic therapy, and that is the right frame. The natural-versus-synthetic split is not a vibes argument about purity. It is a real pharmacological question with real regulatory consequences, and right now it has a preclinical answer and a human-sized hole where the evidence should be.
Here is the state of play in three sentences. Mushrooms contain a family of tryptamines and beta-carbolines, not just psilocybin. In mice, a psychedelic mushroom extract produced broader changes in synaptic proteins than the same dose of chemically synthesized psilocybin. Nobody has run that comparison in people.
Everything else in this article is detail on those three sentences — and on why, despite all of it, the drugs in Phase 3 are synthetic.
What is in a mushroom that is not in a capsule
Beyond psilocybin: baeocystin, norbaeocystin, aeruginascin, and beta-carbolines including harmane, harmol, and harmaline. A COMP360-class capsule contains one molecule at a known weight.
Psilocybin is a prodrug. Your body dephosphorylates it into psilocin, and psilocin is what binds serotonin 5-HT2A receptors. That part is identical whether the psilocybin came out of a fruiting body or a reactor. A psilocybin molecule has no memory of its origin.
The difference is everything else in the mushroom. Analytical work on Psilocybe species has repeatedly turned up related tryptamines — baeocystin, norbaeocystin, aeruginascin — plus beta-carboline alkaloids such as harmane, harmol, and harmaline. Beta-carbolines are interesting because that chemical class includes monoamine oxidase inhibitors, which is the mechanism that makes ayahuasca work at all. If mushrooms carry even weak MAO inhibition alongside their tryptamines, the pharmacokinetics of eating a mushroom would not be the pharmacokinetics of swallowing isolated psilocybin.
That is the entourage-effect hypothesis, borrowed from cannabis, where it has had a rough decade of replication. Borrowing the term is not the same as borrowing evidence. The cannabis version is still contested; importing the phrase into mycology imports the marketing energy along with it.
A fixed synthetic capsule is the opposite proposition: one molecule, one weight, no accessory alkaloids, no batch variance. For a regulator that is not a limitation. It is the entire point.
The two studies people are actually citing
Shahar et al. (Molecular Psychiatry, March 2024) compared mushroom extract to synthetic psilocybin in mice and found broader neuroplasticity effects from the extract. Murray et al. (Scientific Reports, March 2026) is a computer simulation, not a lab experiment.
Shahar et al., 2024. Researchers at Hebrew University-Hadassah — Orr Shahar, Alexander Botvinnik, Tzuri Lifschytz, and Bernard Lerer — gave male C57Bl/6j mice either psychedelic mushroom extract or chemically synthesized psilocybin and looked at what happened in the brain. Eleven days later the extract had raised four synaptic proteins (GAP43, synaptophysin, SV2A, PSD95) across more brain regions than the synthetic did. Synaptophysin rose in the striatum under extract and not under synthetic. Metabolomics showed a distinct profile around oxidative stress and energy production.
Molecular Psychiatry, March 12, 2024: https://doi.org/10.1038/s41380-024-02477-w
The authors’ own conclusion is appropriately narrow: further studies are needed to confirm and extend the findings, and to identify which molecules are responsible. That is a research group saying “we found a signal, we do not know the cause.”
Murray et al., 2026. A South African group ran network pharmacology and molecular docking on fifteen bioactive mushroom compounds, found eight that models predict cross the blood-brain barrier, and mapped predicted interactions with forty-four brain proteins. The headline result is that 4-hydroxy-N,N,N-trimethyltryptamine — a degradation product of aeruginascin — may bind serotonin receptors more strongly than psilocin.
Scientific Reports, March 16, 2026: https://doi.org/10.1038/s41598-026-39483-7
Read that carefully. This is a simulation. No mice, no cells, no people. It is a hypothesis-generating computational screen built from databases, and the authors say so, along with a caveat that deserves more circulation than it gets: their findings should not be read to mean whole extracts are safer than synthetic, because some of the receptors involved affect cardiovascular function.
Earlier work points the same direction without settling it — a Psilocybe argentipes extract reduced marble-burying, an anxiety proxy, more effectively than pure psilocybin in mice, without sedating them.
Why every trial still runs on synthetic
Because a clinical trial needs a dose. Compass’s COMP360 is a fixed 25mg synthetic capsule; Usona’s psilocybin is synthetic too. You cannot run a placebo-controlled study against a variable natural product.
If natural might be better, why is nothing in Phase 3 natural?
Because potency in mushrooms is a moving target. Alkaloid content varies by species, by strain, by flush, by growing conditions, by how the material was dried and stored. Two grams of one cultivar is not two grams of another. Our own strain and dosage pages exist precisely because that variance is real: /strains, /dosage, /species.
A regulator cannot approve “about this much of a mushroom.” A trial cannot blind against it. Reproducibility requires a known quantity of a known molecule, which is why Compass Pathways’ COMP360 is a fixed 25mg synthetic capsule and why Usona’s program uses synthetic psilocybin as well. We covered what that package now looks like in /blog/industry-news/psilocybin-brain-reboot-clinical-evidence.
So the honest framing is not “pharma picked the worse molecule.” It is that pharma picked the *measurable* one, and measurement was the precondition for finding out whether any of this works. The entourage question is downstream of that choice, and it can only be answered by a trial someone has not yet run: standardized extract versus matched-dose synthetic, in humans, with the same support structure on both arms.
The regulatory split maps onto the chemistry split
Oregon and Colorado licensed services use natural mushrooms. The FDA track uses synthetic. That is not a coincidence — it is two different regulatory models producing two different products.
This is the part most coverage skips, and it is the part that changes what you can actually do.
Oregon’s regulated psilocybin services and Colorado’s licensed healing centers run on natural mushrooms, with doses chosen by a facilitator inside a supervised session. See /legal-status/oregon and /legal-status/colorado, and the map at /legal-status.
The FDA track runs on synthetic, at fixed milligrams, inside a protocol.
So if the entourage hypothesis eventually holds up in humans, the awkward implication is that the state programs are already delivering the thing the trials are not testing — and the trials are the ones generating the efficacy data that gets cited to justify the state programs. That circularity is worth sitting with before anyone declares a winner.
What it does not mean: that an Oregon session is a stronger version of COMP360, or that a bag of dried cubensis is a clinical dose with bonus alkaloids. Different product, different setting, different evidence base. Do not port the label across. Cost and structure of a supervised session: /blog/industry-news/psilocybin-therapy-cost.
PsyBear takeaways
Interesting hypothesis, preclinical evidence, no human data, and zero implications for how carefully you should approach a dose. Do not let a chemistry debate talk you out of screening and a container.
1. “Natural is stronger” is a hypothesis with mouse support. Shahar 2024 is a real result from a real lab. It is also four synaptic proteins in C57Bl/6j mice, and the authors themselves cannot yet say which molecule did it.
2. A docking simulation is not a finding. Murray 2026 is a computational screen. It generates candidates for future experiments. Anyone citing it as proof that aeruginascin beats psilocin has skipped the methods section — and the authors’ cardiovascular caveat.
3. Nobody has run the human comparison. Until a trial gives one arm standardized extract and another matched-dose synthetic with identical support, the honest answer to the Short’s question is “we do not know.”
4. Synthetic won the trials for a reason that still holds. Milligram precision is what makes a study interpretable. That is not pharma capture; it is what evidence requires.
5. Variance is a safety issue, not a feature. If mushrooms really do carry an active accessory pharmacology, that is also an argument that potency is *less* predictable than the label on a capsule — including for people on serotonergic medication, where beta-carbolines would be exactly the wrong surprise. Start at /guides/safe-trip.
6. None of this changes the container. Screening, set, setting, a sitter, and integration are what the outcome literature keeps pointing at, regardless of which molecule got you there: /guides/psilocybin-therapy and /guides/psychedelic-integration-workbook.
Psilocybin remains a Schedule I substance under U.S. federal law outside licensed state programs and authorized research. This article is education and commentary on preclinical literature, not medical advice, and not a suggestion that mushrooms are safer or more effective than a supervised clinical protocol. Beta-carbolines with MAO-inhibiting activity can interact dangerously with antidepressants and other medications — talk to a clinician, not a comment section.
Key Takeaways
Whole mushrooms contain more than psilocybin — baeocystin, norbaeocystin, aeruginascin, and beta-carbolines like harmane and harmol. A 2024 Molecular Psychiatry study found mushroom extract moved more neuroplasticity markers in mice than chemically synthesized psilocybin at a matched dose, and a 2026 Scientific Reports simulation predicted an aeruginascin breakdown product may bind serotonin receptors more strongly than psilocin. Both are preclinical. Zero human trials have compared extract to synthetic head-to-head. Meanwhile every FDA-track program — COMP360, Usona — uses synthetic, because a trial needs a known number of milligrams. “Natural is stronger” is a live hypothesis, not a finding, and it is not a reason to skip screening or a container.
FAQ
- Is natural psilocybin stronger than synthetic psilocybin?
- There is no human evidence either way. In mice, whole mushroom extract produced broader neuroplasticity effects than matched-dose synthetic psilocybin (Shahar et al., Molecular Psychiatry, 2024). The psilocybin molecule itself is identical from either source; any difference would come from other mushroom compounds, and that has not been tested in people.
- What is the entourage effect in magic mushrooms?
- The hypothesis that compounds besides psilocybin — baeocystin, norbaeocystin, aeruginascin, and beta-carbolines like harmane and harmol — contribute to the overall effect, so a whole mushroom does not act like isolated psilocybin. The term is borrowed from cannabis research, where it remains contested. In mushrooms it is supported by preclinical work only.
- Why do clinical trials use synthetic psilocybin?
- Because a trial needs a known dose. Alkaloid content in mushrooms varies by species, strain, flush, and growing conditions, which makes blinding and reproducibility impossible. Compass Pathways’ COMP360 is a fixed 25mg synthetic capsule; Usona’s program also uses synthetic psilocybin.
- Do Oregon and Colorado use natural or synthetic psilocybin?
- Natural. Oregon’s regulated psilocybin services and Colorado’s licensed healing centers use whole mushrooms at facilitator-chosen doses inside supervised sessions. That is a different product from the fixed synthetic capsules used in FDA-track trials, and the two should not be treated as interchangeable.
- Does the research say mushroom extract is safer than synthetic?
- No, and the 2026 Scientific Reports authors explicitly warn against that reading, noting that some predicted receptor targets affect cardiovascular function. Unpredictable potency and possible MAO-inhibiting beta-carbolines are arguments for more caution with natural material, not less — particularly for anyone taking serotonergic medication.